Home/Filings/4/0001209191-20-007738
4//SEC Filing

Hamel Lawrence G 4

Accession 0001209191-20-007738

CIK 0001427925other

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 9:08 PM ET

Size

8.2 KB

Accession

0001209191-20-007738

Insider Transaction Report

Form 4
Period: 2020-02-06
Hamel Lawrence G
Chief Development Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-02-06+100,000100,000 total
    Exercise: $1.72Exp: 2030-02-06Common Stock (100,000 underlying)
  • Award

    Common Stock

    2020-02-06+50,000133,382 total
Holdings
  • Common Stock

    (indirect: By Trust)
    29,795
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]The restricted stock units shall vest in three equal consecutive annual installments on February 6, 2021, February 6, 2022 and February 6, 2023.
  • [F3]The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the grant date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.

Issuer

ACELRX PHARMACEUTICALS INC

CIK 0001427925

Entity typeother

Related Parties

1
  • filerCIK 0001511368

Filing Metadata

Form type
4
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 9:08 PM ET
Size
8.2 KB